

United States Patent and Trademark Office

UNO1462-US NI

Carey

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

08/905,293 08/01/1997 MA 23914 7590 02/08/2006 LOUIS J. WILLE	E JOANNE ROSOK 030436.46SU1 EXAMINER	5228
23914 7590 02/08/2006	EXAMINER	-
LOING L WILLE		
and the second s	DEVI, SARVAMANG	ALA J N
BRISTOL-MYERS SQUIBB COMPANY PATENT DEPARTMENT	ART UNIT F	APER NUMBER
P O BOX 4000	1645	
PRINCETON, NJ 08543-4000	DATE MAILED: 02/08/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED BWS PATENT LAW

FEB 1 0 2006

Docketed Item

Due Date

Attorney ___

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	АТТ	ORNEY DOCKET NO.	
08/905,293	08/01/97	Rosok et al.	03043	030436.46SU1	
Customer Number 23914		EXAMIN			
	,	·	S. Devi,	S. Devi, Ph.D.	
			ART UNIT	PAPER NUMBER	
			1645	022006	
		_	DATE MAILED:		

Please find below a communication from the EXAMINER in charge of this application Commissioner of Patents

- 1) The instant application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, the instant application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures. It should be noted that 37 CFR 1.821 (a)(2)(c-d) states that each sequence disclosed must appear separately in the "Sequence Listing" and in the text of the description and claims. See MPEP 2431.
- 2) The instant specification includes recitations of nucleotide sequences longer than ten bases, yet does not identify each sequence by a sequence identifier (SEQ ID number) as required under 37 C.F.R 1.821 through 1.825. Each of the complementary sequences in Figures 14A to 14J and Figures 19A to 19N must be identified by specific sequence identifiers. See 37 C.F.R 1.821 through 1.825.
- APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD OF TIME FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R 1.821 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R 1.821(g). Extensions of time may be obtained under the provisions of 37 C.F.R 1.136. In no case may an Applicant extend the period of reply beyond the SIX MONTH statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Serial Number: 08/905,293

Art Unit: 1645

4) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. The Examiner can normally be reached on Monday to Friday from 7.15 a.m to 4.15 p.m. A message may be left on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (571) 272-0864.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

February, 2006

S. DEVI, PH.D.
PRIMARY EXAMINES

Application No.: 08/905,293

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: Each of the complementary sequences depicted in Figures 14A-14J and Figures 19A-19N multiple identified by a SEQ ID number.
Ap	plicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 tentln Software Program Support (SIRA)
	Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE